Identification of prokineticin‐2 as potential pharmacodynamic biomarker for overcoming doxorubicin resistance in multicellular breast cancer spheroids
Our findings provide the first evidence that PK2 may serve as a predictive pharmacodynamic marker, offering a potential strategy to overcome drug resistance in targeted cancer therapy.
Authors
- Michael W.Y. Chan (ORCID: https://orcid.org/0000-0003-1431-322X)
- Canan G. Nebigil (ORCID: https://orcid.org/0000-0002-2035-5795)
- Martina Vincenzi (ORCID: https://orcid.org/0000-0002-3140-4513)
- Roberta Lattanzi (ORCID: https://orcid.org/0000-0002-6377-9256)
- Amin Kremić
- Po‐Yen Hsu
- Nathalie N. Tscheiller
Institutions
- National Chung Cheng University (TW)
- Inserm (FR)
- Regenerative NanoMedicine (FR)
- Sapienza University of Rome (IT)
Publication Details
- Journal
- British Journal of Pharmacology
- Published
- 2025-09-21
- DOI
- https://doi.org/10.1111/bph.70204
- Citations
- 1
- Primary Topic
- Fibroblast Growth Factor Research
- Type
- article
- Field-Weighted Citation Impact
- 0.81
Funders
- Agence Nationale de la Recherche
- Sapienza Università di Roma
- Società Italiana di Farmacologia